39 29

Cited 0 times in

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

DC FieldValueLanguage
dc.contributor.author김진석-
dc.contributor.author양우익-
dc.date.accessioned2020-12-01T17:31:53Z-
dc.date.available2020-12-01T17:31:53Z-
dc.date.issued2020-04-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180316-
dc.description.abstractPurpose: The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30-expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit. Materials and methods: This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30-expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks. The primary endpoint was > 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as ≥ 30% tumor cells positive for CD30 by immunohistochemistry. Results: High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients (13.3%, 2/15). Conclusion: BV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleEfficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSeok Jin Kim-
dc.contributor.googleauthorDok Hyun Yoon-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorHye Jin Kang-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorHyeon-Seok Eom-
dc.contributor.googleauthorJung Yong Hong-
dc.contributor.googleauthorJunhun Cho-
dc.contributor.googleauthorYoung Hyeh Ko-
dc.contributor.googleauthorJooryung Huh-
dc.contributor.googleauthorWoo-Ick Yang-
dc.contributor.googleauthorWeon Seo Park-
dc.contributor.googleauthorSeung-Sook Lee-
dc.contributor.googleauthorCheolwon Suh-
dc.contributor.googleauthorWon Seog Kim-
dc.identifier.doi10.4143/crt.2019.198-
dc.contributor.localIdA01017-
dc.contributor.localIdA02300-
dc.contributor.localIdA02300-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid31476851-
dc.subject.keywordBrentuximab vedotin-
dc.subject.keywordCD30-
dc.subject.keywordMultiple myeloma oncogene-1-
dc.subject.keywordNon-Hodgkin lymphoma-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.affiliatedAuthor김진석-
dc.contributor.affiliatedAuthor양우익-
dc.contributor.affiliatedAuthor양우익-
dc.citation.volume52-
dc.citation.number2-
dc.citation.startPage374-
dc.citation.endPage387-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.52(2) : 374-387, 2020-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.